Malignant pleural mesothelioma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The incidence of malignant pleural mesothelioma (MPM) has risen for some decades and is expected to peak between 2010 and 2020. Up to now, no single treatment has been proven to be effective and death usually occurs within about 12-17 months after diagnosis. Perhaps because of this poor prognosis, early screening has incited little interest. However, certain forms may have a better prognosis when diagnosed early and treated by multimodal therapy or intrapleural immunotherapy. Diagnosis depends foremost on histological analysis of samples obtained by thoracoscopy. This procedure allows the best staging of the pleural cavity with an attempt to detect visceral pleural involvement, which is one of the most important prognostic factors. Although radiotherapy seems necessary and is efficient in preventing the malignant seeding after diagnostic procedures in patients, there has been no randomized phase III study showing the superiority of any treatment compared with another. However, for the early-stage disease (stage I) a logical therapeutic approach seems to be neoadjuvant intrapleural treatment using cytokines. For more advanced disease (stages II and III) resectability should be discussed with the thoracic surgeons and a multimodal treatment combining surgery, radiotherapy and chemotherapy should be proposed for a randomized controlled study. Palliative treatment is indicated for stage IV. In any case, each patient should be enrolled in a clinical trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesothelioma in Cyprus: the role of tremolite
McConnochie, K., Simonato, L., Mavrides, P., Christofides, P., Pooley, F. D., & Wagner, J. C. (1987) · Thorax · doi:10.1136/thx.42.5.342 · Cited by 101 · cited 1×
“Mesothelioma due to nonoccupational environmental exposure has been reported in various places including Corsica [21], New Caledonia [30], Cyprus [31], Greece [32] and Turkey [33].”
BackgroundSakellariou, K., Malamou-Mitsi, V, Haritou, A., Koumpaniou, C., Stachouli, C., Dimoliatis, I., & Constantopoulos, S. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09061206 · Cited by 62 · cited 1×
“Mesothelioma due to nonoccupational environmental exposure has been reported in various places including Corsica [21], New Caledonia [30], Cyprus [31], Greece [32] and Turkey [33].”
Background
Cited by
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Donaldson, K., Murphy, F. A., Duffin, R., & Poland, C. A. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-5 · Cited by 916
Robinson, B. W., Musk, A. W., & Lake, R. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67025-0 · Cited by 664
Mesothelin-family proteins and diagnosis of mesothelioma
Robinson, B. W., Creaney, J., Lake, R., Nowak, A., Musk, A. W., de Klerk, N., Winzell, P., Hellstrom, K. E., & Hellstrom, I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14794-0 · Cited by 534
Management of Malignant Pleural Effusions
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.5.ats8-00 · Cited by 498
Metadata
- Authors
- Boutin, C., Schlesser, M., Frenay, C., & Astoul, P.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 1998-10-01
- Volume
- 12
- Issue
- 4
- Pages
- 972-981
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2096085739
- Cited by
- 175
- References
- 2
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Malignant pleural mesothelioma. https://app.cochat.ai/papers/10.1183/09031936.98.12040972
- The paper
- Boutin, C., Schlesser, M., Frenay, C., & Astoul, P. (1998). Malignant pleural mesothelioma. European Respiratory Journal. https://doi.org/10.1183/09031936.98.12040972
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.